

# Jamie Berta Spangler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1526901/publications.pdf>

Version: 2024-02-01

34  
papers

1,629  
citations

516561

16  
h-index

414303

32  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2377  
citing authors

#	ARTICLE	IF	CITATIONS
1	De novo design of potent and selective mimics of IL-2 and IL-15. <i>Nature</i> , 2019, 565, 186-191.	13.7	362
2	Insights into Cytokine Receptor Interactions from Cytokine Engineering. <i>Annual Review of Immunology</i> , 2015, 33, 139-167.	9.5	204
3	Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. <i>Immunity</i> , 2015, 42, 815-825.	6.6	191
4	Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps. <i>Immunity</i> , 2015, 42, 826-838.	6.6	147
5	Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13252-13257.	3.3	135
6	Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. <i>Cell</i> , 2021, 184, 983-999.e24.	13.5	78
7	Multifarious Determinants of Cytokine Receptor Signaling Specificity. <i>Advances in Immunology</i> , 2014, 121, 1-39.	1.1	62
8	Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. <i>Journal of Immunology</i> , 2018, 201, 2094-2106.	0.4	58
9	Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. <i>ELife</i> , 2017, 6, .	2.8	51
10	Suspendable Hydrogel Nanovials for Massively Parallel Single-Cell Functional Analysis and Sorting. <i>ACS Nano</i> , 2022, 16, 7242-7257.	7.3	35
11	Effect of Pathogenic Cysteine Mutations on FGFR3 Transmembrane Domain Dimerization in Detergents and Lipid Bilayers. <i>Biochemistry</i> , 2007, 46, 11039-11046.	1.2	31
12	Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression. <i>Journal of Molecular Biology</i> , 2012, 422, 532-544.	2.0	30
13	Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2005, 1668, 240-247.	1.4	28
14	Engineered antibody fusion proteins for targeted disease therapy. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 1064-1081.	4.0	23
15	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. <i>JCI Insight</i> , 2022, 7, .	2.3	23
16	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	21
17	Strategies for Glycoengineering Therapeutic Proteins. <i>Frontiers in Chemistry</i> , 2022, 10, 863118.	1.8	19
18	Targeting cancer metastasis with antibody therapeutics. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1698.	3.3	17

#	ARTICLE	IF	CITATIONS
19	A strategy for the selection of monovalent antibodies that span protein dimer interfaces. <i>Journal of Biological Chemistry</i> , 2019, 294, 13876-13886.	1.6	16
20	Antibody- $\alpha$ -Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers. <i>Journal of the American Chemical Society</i> , 2022, 144, 11226-11237.	6.6	13
21	Reprogramming immune proteins as therapeutics using molecular engineering. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 27-34.	3.8	9
22	Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. <i>Molecular Therapy</i> , 2022, 30, 3430-3449.	3.7	8
23	Emerging technologies in protein interface engineering for biomedical applications. <i>Current Opinion in Biotechnology</i> , 2019, 60, 82-88.	3.3	7
24	A suspension cell-based interaction platform for interrogation of membrane proteins. <i>AIChE Journal</i> , 2020, 66, e16995.	1.8	7
25	Insights into the anticancer mechanisms of interleukin-15 from engineered cytokine therapies. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	5
26	Structural Basis for Signaling Through Shared Common $\beta$ Chain Cytokines. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1172, 1-19.	0.8	3
27	Weaponizing T-cell receptors through molecular engineering. <i>Journal of Biological Chemistry</i> , 2019, 294, 5805-5806.	1.6	2
28	Structure-Guided Molecular Engineering of a Vascular Endothelial Growth Factor Antagonist to Treat Retinal Diseases. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 405-418.	1.0	2
29	Characterization of Immune Cell Subset Expansion in Response to Therapeutic Treatment in Mice. <i>Methods in Molecular Biology</i> , 2020, 2111, 101-114.	0.4	2
30	A Hybrid Adherent/Suspension Cell-Based Selection Strategy for Discovery of Antibodies Targeting Membrane Proteins. <i>Methods in Molecular Biology</i> , 2022, 2491, 195-216.	0.4	2
31	Innovative synthetic signaling technologies for immunotherapy. <i>Current Opinion in Biomedical Engineering</i> , 2020, 16, 1-8.	1.8	1
32	A versatile design platform for glycoengineering therapeutic antibodies. <i>MAbs</i> , 2022, 14, .	2.6	1
33	Full speed AHEAD in antibody discovery. <i>Nature Chemical Biology</i> , 2021, 17, 1011-1012.	3.9	0
34	Joined at the hip: The role of light chain complementarity determining region 2 in antibody self-association. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	0